Masashi Kawabori

Masashi Kawabori

Auto-generated profile, based on publicly available information

Masashi Kawabori

Division of Cardiac Surgery, University of Kentucky, Lexington, Kentucky

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in ASAIO Journal
Verified
Journal Article
Closed access
MZMina Zaky
Mina Zaky
TNTaylor Nordan
Taylor Nordan
NKNavin K. Kapur
Navin K. Kapur
AVAmanda R. Vest
Amanda R. Vest
DDDavid DeNofrio
David DeNofrio
MKMasashi Kawabori
Masashi Kawabori
Prolonged mechanical circulatory support (MCS) for severe left ventricular dysfunction in cardiogenic shock as a bridge to heart transplantation (HTx) generally requires a surgical procedure. Typically, a surgically implanted temporary extracorporeal left ventricular assist device (LVAD) is chosen because of superior flow and durability compared with a percutaneously delivered endovascular LVAD (pVAD). However, compared with its predecessors, the Impella 5.5 trans-valvular pVAD provides higher hemodynamic support and features improved durability. Here, we present four successful cases with prolonged Impella 5.5 support as a bridge to HTx, with a mean support duration of 70 days (maximum 83 days). These cases highlight several potential benefits of Impella 5.5. The minimally invasive implantation procedure of the device reduces bleeding, decreases the postoperative recovery period, and enables early patient ambulation to reduce physical deconditioning before HTx surgery. Furthermore, Impella 5.5 adequately unloads the left ventricle and provides hemodynamic support to maintain end-organ function to further optimize hemodynamics before HTx. The evolution of Impella 5.5 technology may provide an alternative bridging strategy to traditional surgically implanted temporary MCS in select cases.

1 May 2021 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
TNTaylor Nordan
Taylor Nordan
ACAndre C. Critsinelis
Andre C. Critsinelis
SMShant H. Mahrokhian
Shant H. Mahrokhian
NKNavin K. Kapur
Navin K. Kapur
KTKatherine L. Thayer
Katherine L. Thayer
MKMasashi Kawabori
Masashi Kawabori
Background: The effect of the new donor heart allocation system on survival following bridging to transplantation with venous-arterial extracorporeal membrane oxygenation remains unknown. The new allocation system places extracorporeal membrane oxygenation–supported candidates at the highest status. Methods: The United Network for Organ Sharing database was queried for adults bridged to single-organ heart transplantation with extracorporeal membrane oxygenation from October 2006 to February 2020. Association between implementation of the new system and recipient survival was analyzed using Kaplan-Meier estimates, Cox proportional hazards models, and propensity score matching. Results: Of 364 recipients included, 173 and 191 were transplanted under new and old systems, respectively. Compared with the old system, waitlist time was halved under the new system (5 versus 10 days, P <0.01); recipients also demonstrated lower rates of prior cardiac surgery (32.9% versus 44.5%, P =0.03) and preoperative ventilation (30.6% versus 42.4%, P =0.02). Unadjusted 180-day survival was 90.2% (95% CI, 84.7%–94.2%) and 69.6% (95% CI, 62.6%–76.1%) under the new and old systems, respectively. Cox proportional hazards analysis demonstrated listing and transplantation under the new system to be an independent predictor of post-transplant survival (adjusted hazard ratio, 0.34 [95% CI 0.20–0.59]). Propensity score matching demonstrated a similar trend (hazard ratio, 0.36 [95% CI, 0.19–0.66]). Candidates listed under the new system were significantly less likely to experience waitlist mortality or deterioration (subhazard ratio, 0.38 [95% CI, 0.25–0.58]) and more likely to survive to transplant (subhazard ratio, 4.29 [95% CI, 3.32–5.54]). Conclusions: Recipients transplanted following extracorporeal membrane oxygenation bridging to transplantation under the new system achieve greater 180-day survival compared with the old and demonstrate less preoperative comorbidity. Waitlist outcomes have also improved significantly under the new allocation system.

23 February 2018 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
CKChitaru Kurihara
Chitaru Kurihara
MKMasashi Kawabori
Masashi Kawabori
TSTadahisa Sugiura
Tadahisa Sugiura
ACAndre C. Critsinelis
Andre C. Critsinelis
SWSuwei Wang
Suwei Wang
JMJeffrey A. Morgan
Jeffrey A. Morgan

5 April 2022 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
AVAmanda R. Vest
Amanda R. Vest
WWWilliam W. Wong
William W. Wong
JCJoronia Chery
Joronia Chery
ACAlex Coston
Alex Coston
LTLaura Telfer
Laura Telfer
ESEdward Saltzman
Edward Saltzman
Background: Patients with advanced systolic heart failure are at risk of unintentional weight loss and muscle wasting. It has been observed that left ventricular assist device (LVAD) recipients gain weight after device implantation, although it is unknown whether this represents skeletal muscle mass gains. We aimed to determine whether skeletal muscle mass increases early during LVAD support. Methods: We prospectively recruited 30 adults with systolic heart failure ±21 days from LVAD implantation. Participants underwent whole-body dual X-ray absorptiometry to measure fat free mass, appendicular lean mass (ALM, lean mass in the arms and legs) and fat mass. Dual X-ray absorptiometry imaging was repeated at 3 and 6 months after LVAD implantation, with participation ending after the 6-month visit or heart transplantation, whichever occurred first. Changes in body composition were evaluated using mixed effects linear regression models. Results: The cohort was 87% male, with mean age 56±12 (SD) years, and mean body mass index 26.4±5.4 kg/m 2 . Per sarcopenia ALM criteria, 52% of participants had muscle wasting at baseline. At baseline, mean fat free mass and ALM were 56.4±11.7 and 21.0±5.3 kg, respectively. Both measures increased significantly ( P <0.001) over 6 months of LVAD support: mean fat free mass change at 3 and 6 months: 2.3 kg (95% CI, 1.0–3.5) and 4.2 kg (95% CI, 2.2–6.1); mean ALM change at 3 and 6 months: 1.5 kg (95% CI, 0.7–2.3) and 2.3 kg (95% CI, 0.9–3.6). Conclusions: Among LVAD recipients with advanced systolic heart failure and high baseline prevalence of muscle wasting, there were significant gains in skeletal muscle mass, as represented by dual X-ray absorptiometry fat free mass and ALM, over the first 6 months of LVAD support.

23 April 2024 in Circulation
Verified
Journal Article
Closed access
LSLija Swain
Lija Swain
SBShreyas Bhave
Shreyas Bhave
XQXiaoying Qiao
Xiaoying Qiao
LRLara Reyelt
Lara Reyelt
KEKay D. Everett
Kay D. Everett
NKNavin K. Kapur
Navin K. Kapur
BACKGROUND: Cardiolipin is a mitochondrial-specific phospholipid that maintains integrity of the electron transport chain (ETC) and plays a central role in myocardial ischemia/reperfusion injury. Tafazzin is an enzyme that is required for cardiolipin maturation. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) use to provide hemodynamic support for acute myocardial infarction has grown exponentially, is associated with poor outcomes, and is under active clinical investigation, yet the mechanistic effect of VA-ECMO on myocardial damage in acute myocardial infarction remains poorly understood. We hypothesized that VA-ECMO acutely depletes myocardial cardiolipin and exacerbates myocardial injury in acute myocardial infarction. METHODS: We examined cardiolipin and tafazzin levels in human subjects with heart failure and healthy swine exposed to VA-ECMO and used a swine model of closed-chest myocardial ischemia/reperfusion injury to evaluate the effect of VA-ECMO on cardiolipin expression, myocardial injury, and mitochondrial function. RESULTS: Cardiolipin and tafazzin levels are significantly reduced in the left ventricles of individuals requiring VA-ECMO compared with individuals without VA-ECMO before heart transplantation. Six hours of exposure to VA-ECMO also decreased left ventricular levels of cardiolipin and tafazzin in healthy swine compared with sham controls. To explore whether cardiolipin depletion by VA-ECMO increases infarct size, we performed left anterior descending artery occlusion for a total of 120 minutes followed by 180 minutes of reperfusion in adult swine in the presence and absence of MTP-131, an amphipathic molecule that interacts with cardiolipin to stabilize the inner mitochondrial membrane. Compared with reperfusion alone, VA-ECMO activation beginning after 90 minutes of left anterior descending artery occlusion increased infarct size (36±8% versus 48±7%; P <0.001). VA-ECMO also decreased cardiolipin and tafazzin levels, disrupted mitochondrial integrity, reduced electron transport chain function, and promoted oxidative stress. Compared with reperfusion alone or VA-ECMO before reperfusion, delivery of MTP-131 before VA-ECMO activation reduced infarct size (22±8%; P =0.03 versus reperfusion alone and P <0.001 versus VA-ECMO alone). MTP-131 restored cardiolipin and tafazzin levels, stabilized mitochondrial function, and reduced oxidative stress in the left ventricle. CONCLUSIONS: We identified a novel mechanism by which VA-ECMO promotes myocardial injury and further identify cardiolipin as an important target of therapy to reduce infarct size and to preserve mitochondrial function in the setting of VA-ECMO for acute myocardial infarction.

1 July 2022 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
TNTaylor Nordan
Taylor Nordan
ACAndre C. Critsinelis
Andre C. Critsinelis
SMShant H. Mahrokhian
Shant H. Mahrokhian
NKNavin K. Kapur
Navin K. Kapur
AVAmanda Vest
Amanda Vest
MKMasashi Kawabori
Masashi Kawabori